Drugs / NB-1008
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01354379 | May 2011 → Jun 2012 | — | NanoBio Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01333462 | Mar → Aug 2009 | — | NanoBio Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NB-1008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01354379 ↗ |
| Modality | Vaccine | “a new intranasal vaccine against influenza, called NB-1008” NCT01333462 ↗ |
| Route | Intranasal | “a new intranasal vaccine against influenza, called NB-1008” NCT01333462 ↗ |